Cited by 1,999Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Open access

Bonaca, Marc P., Bhatt, Deepak L., Cohen, Marc, Steg, Philippe Gabriel, Storey, Robert F., Jensen, Eva C., Magnani, Giulia, Bansilal, Sameer, Fish, M. Polly, Im, Kyungah, Bengtsson, Olof, Ophuis, Ton Oude, Budaj, Andrzej, Theroux, Pierre, Ruda, Mikhail, Hamm, Christian, Goto, Shinya, Spinar, Jindrich, Nicolau, José Carlos, Kiss, Robert G., Murphy, Sabina A., Wiviott, Stephen D., Held, Peter, Braunwald, Eugene, Sabatine, Marc S.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1500857

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P=0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P<0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1500857

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary
Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E., Green, L. A., Hand, M. M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,348
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Authors Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Mario, C. D., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,890
Self-citation
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,802
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Self-citation
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
(2009) · The Lancet · doi:10.1016/s0140-6736(09)60503-1 · Cited by 3,675

Flagged first, then by citations

Show all 32 references

1 of the 32 references couldn’t be matched to a known paper.

Sorted by citations

Items 701–800 of 999

A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease
Marquis‐Gravel, G., Mehta, S. R., Valgimigli, M., Levine, G. N., Neumann, F., Granger, C. B., Costa, F., Lordkipanidzé, M., Roffi, M., Robinson, S. D., et al. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.12.013 · Cited by 14
Prognostic significance of suboptimal secondary prevention pharmacotherapy after acute coronary syndromes
Yudi, M., Farouque, O., Andrianopoulos, N., Ajani, A. E., Brennan, A., Murphy, A. C., Lefkovits, J., Reid, C. M., Oqueli, E., Sebastian, M., et al. (2020) · Internal Medicine Journal · doi:10.1111/imj.14750 · Cited by 15
Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
Brieger, D. B., Pocock, S., Blankenberg, S., Chen, J. Y., Cohen, M. G., Granger, C. B., Grieve, R., Nicolau, J. C., Simon, T., Westermann, D., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.01.070 · Cited by 14
Self-citation
A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study
Kubica, J., Adamski, P., Niezgoda, P., Kubica, A., Podhajski, P., Barańska, M., Umińska, J. M., Pietrzykowski, Ł., Ostrowska, M., Siller-Matula, J. M., et al. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0056 · Cited by 13
Self-citation
2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome
Tan, J. W. C., Chew, D. P., Brieger, D. B., Eikelboom, J. W., Montalescot, G., Ako, J., Kim, B., Quek, D. K., Aitken, S., Chow, C. K., et al. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.45 · Cited by 13
Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents
Lim, S., Choo, E. H., Choi, I. J., Lee, K. Y., Lee, S. N., Hwang, B., Kim, C. J., Park, M., Lee, J. M., Park, C. S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163642 · Cited by 12
“Although the risks of MI and stroke were lower in the present study than in Western national health records studies and one randomized trial that included high-risk patients without history of PCI [13,23,25], the rates in our study were similar to those in Asian registry studies and other randomized trials that includ…”
Result
Ticagrelor for prevention of stroke and cognitive impairment in patients with vascular high-risk factors: A meta-analysis of randomized controlled trials
Li, X., Jia, Z., & Yan, Y. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.01.060 · Cited by 13
Summary of the European Society of Cardiology guidelines on dual antiplatelet therapy in patients after percutaneous coronary interventions
Hudzik, B., Błachut, A., Lesiak, M., Kubica, J., Wojakowski, W., & Gąsior, M. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0198 · Cited by 18
Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges
Caterina, R. D., & Goto, S. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.03.003 · Cited by 13
Self-citation
Dual antiplatelet therapy after coronary stenting
Park, Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1202924 · Cited by 13
“The Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial evaluated the safety and efficacy of extending DAPT duration with aspirin and ticagrelor (used in two different do…”
BackgroundMethodInfluential
Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events
Al-Salama, Z. T., Keating, G. M., & Keam, S. J. (2017) · Drugs · doi:10.1007/s40265-017-0844-8 · Cited by 14
Selection of P2Y 12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
Tantry, U. S., Navarese, E. P., Myat, A., & Gurbel, P. A. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.01.003 · Cited by 13
Differences in thromboembolism after stent-assisted coiling for unruptured aneurysms between aspirin plus clopidogrel and ticagrelor
Kim, S. H., Lee, H., Kim, S. B., Kim, S. T., Baek, J. W., Heo, Y. J., Jeong, H. W., Kim, H. J., Park, J. H., Kim, J. S., et al. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.10.042 · Cited by 13
Predicting long‐term bleeding after percutaneous coronary intervention
Sharma, P. K., Chhatriwalla, A. K., Cohen, D. J., Jang, J., Baweja, P. S., GOSCH, K. L., Jones, P. G., Bach, R. G., Arnold, S. V., & Spertus, J. A. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26529 · Cited by 13
“Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) study [18] evaluated long-term DAPT with aspirin and ticagrelor beyond 1 year following PCI, and demonstrated a lower incide…”
Method
The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease
Turgeon, R. D., Ackman, M. L., Babadagli, H. E., Basaraba, J. E., Chen, J. W., Omar, M. A., & Zhou, J. S. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418795889 · Cited by 14
“Moreover, extending DAPT beyond 1 year in patients with previous ACS or PCI provides minimal additional thrombotic protection and does not reduce the risk of death.(6,7) Five direct oral anticoagulants (DOACs) are now available in North America: apixaban, betrixaban, dabigatran, edoxaban, and rivaroxaban.”
Background
Dual Antiplatelet Therapy in Percutaneous Coronary Intervention
Piccolo, R., & Windecker, S. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.003587 · Cited by 13
Composite endpoints and the distortion of risk–benefit analysis
Warren, J. B. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13166 · Cited by 13
Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction
Small, A. M., Yang, T.-Y., Itoh, S., Thériault, S., Dufresne, L., Kurosawa, R., Komuro, I., Matsuda, K., Vy, H. M. T., Farber-Eger, E. H., et al. (2026) · Nature Genetics · doi:10.1038/s41588-025-02417-6 · Cited by 18
Self-citation
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial
Kang, D., Wee, S.-B., Ahn, J., Park, H., Yun, S.-C., Park, K., Kang, S. H., Suh, J., Bae, J., Park, S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf652 · Cited by 14
Use and misuse of composite endpoints in randomised clinical trials
Siquier-Padilla, J., Manzanares, R. G., & Rosselló, X. (2025) · Heart · doi:10.1136/heartjnl-2025-326545 · Cited by 12
“However, due to an unexpected low number of events, it was modified to include a wider spectrum of outcomes: non-fatal MI, atrial fibrillation/flutter, incident type 2 diabetes mellitus, New York Heart Association (NYHA) functional class and reduction in body weight.”
Influential
Intracranial Bleeding After Percutaneous Coronary Intervention: Time‐Dependent Incidence, Predictors, and Impact on Mortality
Lee, P. H., Park, S., Nam, H., Kang, D., Kang, S., Lee, S., Kim, Y., Park, S., & Lee, C. W. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019637 · Cited by 12
Long-term Management of Patients with Myocardial Infarction: An Updated Review
Chen, R., Zhao, H., & Yan, H. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000073 · Cited by 12
“[15,16] However, in recent years, some studies have demonstrated the advantages of shortened DAPT, including a reduced bleeding risk with adequate prevention of ischemic events,[1–4] while others indicate that extended DAPT and the addition of oral anti-coagulants are also clinically beneficial approaches.[18,19] Evid…”
Method
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
Bonaca, M. P., Bhatt, D. L., Simon, T., Fox, K. M., Mehta, S. R., Harrington, R. A., Leiter, L. A., Capell, W. H., Held, C., Himmelmänn, A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.377 · Cited by 12
Self-citation
Prevalencia y pronóstico de los pacientes con infarto de miocardio de alto riesgo candidatos a doble tratamiento antiagregante prolongado
Marrugat, J., Elosúa, R., Grau, M., Sayols-Baixeras, S., & Degano, I. R. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.12.022 · Cited by 12
“50 años 131 (124-138) 45 (41-49) 11 (9,1-13,3)”
Influential
Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions
Everaert, B., Wykrzykowska, J. J., Koolen, J., van der Harst, P., den Heijer, P., Henriques, J. P. S., van der Schaaf, R. J., de Smet, B. J. G. L., Hofma, S. H., Diletti, R., et al. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-1014-z · Cited by 12
“Recently, the PEGASUS-TIMI 54 trial [35] evaluated long-term therapy with ticagrelor in addition to aspirin, in patients with a history of spontaneous MI occurring 1–3 years prior to randomisation.”
Method
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions
Spinthakis, N., Farag, M., Rocca, B., & Gorog, D. A. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007754 · Cited by 13
Strategies for the Prevention of Coronary Artery Disease Complications: Can We Do Better?
Ambrose, J. A., & Najafi, A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.04.006 · Cited by 12
Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy
Reid, C., AlTurki, A., Yan, A. T.-K., So, D. Y. F., Ko, D. T., Tanguay, J., Bessissow, A., Mehta, S. R., Goodman, S. G., & Huynh, T. T. (2020) · CJC Open · doi:10.1016/j.cjco.2020.02.005 · Cited by 12
Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1‐year after coronary artery bypass grafting
Tang, C., Zhu, Y., Yang, X., Xu, B., Ye, C., Yang, Y., Zhong, J., Zhao, Q., & Yu, L. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15030 · Cited by 12
Current and emerging drug treatment strategies for peripheral arterial disease
Essa, H., Torella, F., & Lip, G. Y. H. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774556 · Cited by 12
“In 2015 DAPT was further evaluated in the PEGASUS-TIMI (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction) trial [52].”
Method
Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials
Bauersachs, R. M., Wu, O., Brière, J., Bowrin, K., Borkowska, K., Jakubowska, A., Taieb, V., Toumi, M., & Huelsebeck, M. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/3057168 · Cited by 13
“Recently published studies that evaluated ticagrelor, EUCLID [29] and PEGASUS-TIMI 54 [30], were not included because they included only patients with symptomatic PAD and with prior myocardial infarction, respectively.”
Adverse events beyond 1 year after percutaneous coronary intervention
Madhavan, M. V., & Stone, G. W. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000792 · Cited by 13
The Role and Molecular Mechanism of P2Y12 Receptors in the Pathogenesis of Atherosclerotic Cardiovascular Diseases
Wang, L., Wang, J., Xu, J., Qin, W., Wang, Y., Luo, S., & Wang, G. (2021) · Applied Sciences · doi:10.3390/app11199078 · Cited by 12
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_19 · Cited by 12
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
Harbi, M. H., Smith, C. W., Alenazy, F. O., Nicolson, P. L. R., Tiwari, A., Watson, S. P., & Thomas, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136982 · Cited by 13
“After one year of DAPT, patients with ACS are treated with aspirin alone as the bleeding risk at this stage with P2Y12 inhibitors generally outweighs the antithrombotic benefit [1].”
Novel risk factors for acute coronary syndromes and emerging therapies
Tong, D. C., Wilson, A., & Layland, J. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.148 · Cited by 12
Ticagrelor: agonising over its mechanisms of action
Parker, W. A., & Storey, R. F. (2016) · Blood · doi:10.1182/blood-2016-10-743930 · Cited by 12
Self-citation
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study
Parker, W. A., Bhatt, D. L., Prats, J., Day, J. R., Steg, P. G., Stone, G. W., Hamm, C. W., Mahaffey, K. W., Price, M. J., Gibson, C. M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0958 · Cited by 12
“lor 60 mg twice-daily was associated with similar levels of platelet P2Y12 inhibition but numerically lower rates of dyspnoea compared with ticagrelor 90 mg twice-daily in PEGASUS-TIMI 54, suggesting a closer association between plasma ticagrelor levels and dyspnoea rather than levels of P2Y12 inhibition (6, 15).”
MethodSelf-citation
Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease
Pelletier‐Galarneau, M., Hunter, C. R. R. N., Ascah, K. J., Beanlands, R. S., Dwivedi, G., deKemp, R. A., Chow, B. J. W., & Ruddy, T. D. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005894 · Cited by 12
Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison of Patients with ST Elevation Versus Non-ST Elevation Myocardial Infarction
Zeymer, U., Riedel, K., & Hahn, M. (2017) · Cardiology and Therapy · doi:10.1007/s40119-017-0093-7 · Cited by 12
“Therefore, we used the criteria suggested by the PEGASUS investigators to determine high risk populations [13], which include age[65 years, impaired renal function, diabetes mellitus, a second myocardial infarction or multivessel coronary artery disease.”
MethodResult
Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects
Teng, R., Hammarberg, M., Carlson, G. F., Bokelund-Singh, S., Ruderfelt, T., & Blychert, E. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0554-8 · Cited by 12
“Findings from the PEGASUS-TIMI 54 study showed that long-term therapy (median follow-up 33 months) with ticagrelor significantly reduced the risk of MI/stroke/death from vascular causes versus placebo [6].”
BackgroundMethodInfluential
Antiplatelet therapy for peripheral artery disease
Melfi, R., & Ricottini, E. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.07.02 · Cited by 12
A new score based on the PEGASUS-TIMI 54 criteria for risk stratification of patients with acute myocardial infarction
Cosentino, N., Campodonico, J., Faggiano, P. M., Metrio, M. D., Rubino, M., Milazzo, V., Sbolli, M., Perego, C., Provini, M., Bonomi, A., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.142 · Cited by 12
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
Amilon, C., Niazi, M., Berggren, A., Åstrand, M., & Hamrén, B. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00758-0 · Cited by 14
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus
Calderone, D., Capodanno, D., & Angiolillo, D. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1792293 · Cited by 12
Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes
Liu, Z., Tian, R., Wang, Y., Chen, Q., Li, J., Xu, L., & Zhang, S. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1713375 · Cited by 11
Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
Chen, C., Kan, Y., Shi, Z., Guo, D., Fu, W., Li, Y., Lv, Q., Li, X., & Si, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.608247 · Cited by 12
“Although a variety of strategies have been explored to improve long-term outcomes of acetylsalicylic acid (ASA) therapy (CAPRIE Steering Committee, 1996; Bhatt et al., 2006; Bonaca et al., 2015; Hiatt et al., 2017; Bhatt et al., 2019; Mehran et al., 2019), optimal long-term antithrombotic therapy for chronic vascular…”
Background
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial
Gragnano, F., Zwahlen, M., Vranckx, P., Heg, D., Schmidlin, K., Hamm, C. W., Steg, P. G., Gargiulo, G., McFadden, E. P., Onuma, Y., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024291 · Cited by 12
Self-citation
Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations
FITCHETT, D. H., Goodman, S. G., Leiter, L. A., Lin, P., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., & Langer, A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.03.002 · Cited by 12
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
Singh, M., Bhatt, D. L., Stone, G. W., Rihal, C. S., Gersh, B. J., Lennon, R. J., Narula, J., & Fuster, V. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.013 · Cited by 11
Self-citation
Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain)
Ribera, A., González, I. F., Marsal, J. R., Oristrell, G., Faixedas, M. T., Rosas, A., Tizón‐Marcos, H., Rojas, S., Labata, C., Cárdenas, M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028114 · Cited by 12
Antiplatelet Therapy in Patients with Coronary Disease and Type 2 Diabetes
Bates, E. (2019) · New England Journal of Medicine · doi:10.1056/nejme1910813 · Cited by 12
P2 Purinergic Receptors in Tumor Immunity
Wang, X., Jiang, S., Ma, M., Cai, S., Song, D., & Han, B. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4624 · Cited by 11
Acute ST-Segment Elevation Myocardial Infarction (STEMI)
Lee, J., Reyes, F. M., & Budzikowski, A. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-89725-7_7 · Cited by 11
Reversal of Platelet Inhibition in Patients Receiving Ticagrelor
Adamski, P., Skonieczny, G. K., Hajdukiewicz, T., Kern, A., & Kubica, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2309300 · Cited by 11
“Although bleeding seems to occur less often during treatment with reduced maintenance dose of 60 mg twice daily, it still leads to discontinuation of treatment in 6.2% of patients [26].”
BackgroundInfluential
Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors
Levens, A. D., den Haan, M. C., Jukema, J. W., Heringa, M., van den Hout, W. B., Moes, D. J. A. R., & Swen, J. J. (2023) · Genes · doi:10.3390/genes14030578 · Cited by 11
“The observation of patients being on a prolonged DAPT regimen in our study is no anomaly; both the DAPT study [49] and the PEGASUS-TIMI trial [50] showed a significant reduction in cardiovascular ischemic events with DAPT beyond 1 year after index PCI, albeit paired with an increased risk of bleeding, as compared with…”
Result
One-month DAPT with ticagrelor and aspirin for patients undergoing coronary artery bypass grafting: rationale and design of the randomised, multicentre, double-blind, placebo-controlled ODIN trial
Sandner, S. E., Gaudino, M. F. L., Redfors, B., Angiolillo, D. J., Ben‐Yehuda, O., Bhatt, D. L., Fremes, S. E., Lamy, A. L., Marano, R., Mehran, R., et al. (2024) · EuroIntervention · doi:10.4244/eij-d-23-00699 · Cited by 11
Self-citation
Chinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2023 edition)
Chinese College of Cardiovascular Physicians (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000079 · Cited by 12
Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome
Kaufmann, C. C., Muthspiel, M., Lunzer, L., Pogran, E., Zweiker, D., Burger, A. L., Wojta, J., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082313 · Cited by 12
“…54 trial, showing a significant risk reduction in MACE for an extended ticagrelor-based DAPT (60 mg ticagrelor BID) regimen in ACS patients with at least one ischemic risk factor when compared to aspirin monotherapy after 12 months of DAPT (HR 0.84; 95% CI, 0.74 to 0.95, p = 0.004) [45].”
BackgroundInfluential
Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial
Piccolo, R., Simonetti, F., Avvedimento, M., Cutillo, M., Canonico, M. E., Conti, V., Gargiulo, G., Paolillo, R., Piaz, F. D., Filippelli, A., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae054 · Cited by 12
Machine learning derived model for the prediction of bleeding in dual antiplatelet therapy patients
Yang, Q., Wanling, L., & Maofeng, W. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1402672 · Cited by 11
“Commonly used scoring systems including PARIS (9), CRUSADE (10), ARC-HBR (11), ACUITY-HORIZONS (12), BleeMACS (13), TIMI risk score (14), HAS-Bled score (15), GRACE score (10), and CHA2DS2-VASC score (16) are extensively employed in clinical practice.”
Method
Clickable liposomes for on-demand reversal of antiplatelet drugs: Towards a safe management of bleeding risks associated with antithrombotic therapy
Cheng, X., Wang, C., Xu, J., Huang, Y., Chen, Z., Zhong, L., Du, C., Nie, G., & Zhang, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.070 · Cited by 13
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis
Mee, X. C., Lim, G. K., Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Allam, M., Bcharah, G., Tan, M. C., Barry, T., Farina, J., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf026 · Cited by 11
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation
Jurgens, S. J., Melloni, G. E. M., Kany, S., Fabritz, L., Rämö, J. T., Goette, A., Kamanu, F., Berg, D. D., Magnussen, C., Choi, S. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.052 · Cited by 15
Self-citation
Riesgo cardiovascular a largo plazo tras un síndrome coronario agudo, todavía un reto
Bueno, H., & Martín‐Asenjo, R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.08.019 · Cited by 11
Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling
Almquist, J. O., Penney, M., Pehrsson, S., Sandinge, A., Janefeldt, A., Maqbool, S., Madalli, S., Goodman, J., Nylander, S., & Gennemark, P. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12089 · Cited by 11
“In addition, in the recently completed PEGASUS TIMI-54, the benefit-risk profile for long-term treatment with ticagrelor in patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event was documented supporting the use of ticagrelor for long-term treatment.(5) However, all a…”
Background
Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease
Mauri, L., & Smith, S. C. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2171 · Cited by 11
Mortality and cancer after 12 versus 30 months dual antiplatelet therapy
Cabrera-Fuentes, H. A., Lee, K., Cho, Y., Park, K., Park, T., Kim, Y., Yoon, S.-C., Serebruany, V. L., & Kim, M. H. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0971 · Cited by 11
Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review
Lee, Y. J., Kim, H., Choi, J., Lee, B. H., & Lee, S. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s152276 · Cited by 11
Differential Prognostic Impact on Mortality of Myocardial Infarction Compared With Bleeding Severity in Contemporary Acute Coronary Syndrome Patients
Caneiro‐Queija, B., Abu‐Assi, E., Raposeiras‐Roubín, S., Manzano‐Fernández, S., Blanco, P. F., López‐Cuenca, Á., Paz, R. C., Gómez-Molina, M., Rodríguez-Rodríguez, J. M., Calvo, F., et al. (2018) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.02.008 · Cited by 11
Rivaroxaban: searching the integral vascular protection
Barrios, V., Almendro‐Delia, M., Fácila, L., García–Moll, X., Mazón, P., Camafort, M., Cepeda, J. M., García, J. D. M., Reino, A. P., & Fernández, C. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1495559 · Cited by 11
Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified
Andrade, J. G., Deyell, M. W., Wong, G. C., & Macle, L. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.08.028 · Cited by 11
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition
Ramacciotti, E., & Weitz, J. I. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.09.033 · Cited by 11
How to manage patients with polyvascular atherosclerotic disease. Position paper of the International Union of Angiology
Poredoš, P., Blinc, A., Novo, S., & Antignani, P. L. (2021) · International Angiology · doi:10.23736/s0392-9590.20.04518-6 · Cited by 11
Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention
Luca, L. D., & Valgimigli, M. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa107 · Cited by 11
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI
Chiarito, M., Baber, U., Cao, D., Sharma, S. K., Dangas, G., Angiolillo, D. J., Briguori, C., Cohen, D. J., Dudek, D., Džavík, V., et al. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.11.005 · Cited by 11
Self-citation
Sex differences in treatment and outcomes of patients with in‐hospital ST‐elevation myocardial infarction
Stehli, J., Dinh, D. T., Dagan, M., Dick, R., Oxley, S., Brennan, A., Lefkovits, J., Duffy, S. J., & Zaman, S. J. (2022) · Clinical Cardiology · doi:10.1002/clc.23797 · Cited by 11
A study on the improved dissolution and permeability of ticagrelor with sodium oleate in a ternary system
Sohn, J. S., & Choi, J. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.119685 · Cited by 11
Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review
Croix, G. R. S., Lacy, S. C., Gazzhal, A., Ibrahim, M., Gjergjindreaj, M., Pérez, J., Shehadeh, M., Vedantam, K., Torres, C. A., Beohar, N., et al. (2022) · Journal of Interventional Cardiology · doi:10.1155/2022/3111840 · Cited by 11
“In the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-rombolysis In Myocardial Infarction 54) trial, ticagrelor and aspirin were shown to have a benet on the 3-year primary ischemic outcome at the expense of a 1…”
Method
Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach
Gioscia, R., Castagno, C., Verdoia, M., Conti, B., Forliti, E., & Rognoni, A. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i4.142 · Cited by 12
Ticagrelor for the Treatment of Atherosclerotic Disease: Insights From the Parthenon Clinical Development Program
Held, P., Himmelmänn, A., & Ditmarsch, M. (2016) · Future Cardiology · doi:10.2217/fca-2016-0028 · Cited by 11
Self-citation
Switching P2Y12 Receptor Inhibiting Therapies
Rollini, F., Franchi, F., & Angiolillo, D. J. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.08.006 · Cited by 11
Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery
Steely, A. M., CALLAS, P. W., Hohl, P. K., Schneider, D. J., Martino, R. R. D., & Bertges, D. J. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.06.093 · Cited by 11
Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes?
Luca, L. D., Servi, S. D., Musumeci, G., & Bolognese, L. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx034 · Cited by 11
Rationale and design of the long‐Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post–myocardial infarction patients (TIGRIS) study
Westermann, D., Goodman, S. G., Nicolau, J. C., Requena, G., Maguire, A., Chen, J. Y., Granger, C. B., Grieve, R., Pocock, S., Blankenberg, S., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22837 · Cited by 11
“The cumulative rate of the CV composite outcome, including recurrent MI and stroke and CV death, was 18.3% in the first year after a MI.”
MethodInfluentialSelf-citation
Secondary prevention of cardiovascular diseases: current state of the art
Hasenfuss, G. P. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0198 · Cited by 11
“However, after the results of the PEGASUS trial were published [56], in patients with a very high CV risk and no particular bleeding risk a longer therapy (over three years), precisely a combination of ASA 100 mg/day with ticagrelor 60 mg twice a day, may be considered.”
Switching between P2Y12 antagonists – From bench to bedside
Gąsecka, A., Konwerski, M., Pordzik, J., Soplińska, A., Filipiak, K. J., Siller-Matula, J. M., & Postula, M. A. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2019.01.003 · Cited by 11
Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate.
Hb, W., Hp, T., Wang, X.-C., Bai, S.-R., Xn, L., Ln, Z., & Du, R. (2018) · Europe PMC (PubMed Central) · Cited by 11
Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients
Park, S., Kim, Y., Jo, H. A., Lee, S., Kim, M., Yang, B. R., Lee, J., Han, S. S., Lee, H., Lee, J. P., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa037 · Cited by 11
Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline
Wang, H., Dou, K., Wang, Y., Yin, D., Xu, B., & Gao, R.-L. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07030-9 · Cited by 11
Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice
Warden, B. A., Purnell, J. Q., Duell, P. B., Craigan, C., Osborn, D., Cabot, E., & Fazio, S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100144 · Cited by 12
Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis
Xiang, Z., Yang, J. M., Yang, J., Zhang, J., Fan, Z., Yang, C., Di, L., Ma, C., Wu, J., & Huang, Y. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02606-7 · Cited by 12
“Antithrombotic, lipid-lowering, and antihypertensive therapies as well as lifestyle modification have changed coronary heart disease (CHD) prevention; however, the residual incidence of major cardiovascular adverse events remains at 3% every year, even for patients treated with high rates of established secondary prev…”
Background
Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk
Eduardo Fuentes, Q., Wehinger, S., & Trostchansky, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212380 · Cited by 11
“Studies indicate that an intensification of antiplatelet therapy with prasugrel [34], ticagrelor [35], clopidogrel [10], aspirin [36], clopidogrel plus aspirin [37], vorapaxar [38], apixaban [39], or rivaroxaban [40] is associated with an increased efficacy but often with increased bleeding.”
Background
Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art
Al-Abcha, A. K., Radwan, Y., Blais, D. M., Mazzaferri, E. L., Boudoulas, K. D., Essa, E. M., & Gumina, R. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.850028 · Cited by 11
Dual Antiplatelet Therapy with Parenteral P2Y12 Inhibitors: Rationale, Evidence, and Future Directions
Alagna, G., Mazzone, P., Contarini, M., & Andò, G. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10040163 · Cited by 11
“The different types of bleedings according to the GUSTO criteria and MACE at various timeframes (from 48 h to 30 days) were investigated, too.”
BackgroundInfluential
Another side effect of ticagrelor: Atrial fibrillation
Zhang, N., Chen, K., Zhao, J., Xu, G., Li, G., & Liu, T. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.091 · Cited by 11
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg
Jakubowski, J. A., Erlinge, D., Alexopoulos, D. K., Small, D. S., Winters, K. J., Gurbel, P. A., & Angiolillo, D. J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0202-3 · Cited by 11
Bleeding associated with the management of acute coronary syndromes
Silva, K. D., Myat, A., Cotton, J. M., James, S. K., Gershlick, A., & Stone, G. W. (2017) · Heart · doi:10.1136/heartjnl-2015-307602 · Cited by 11
Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation
Olesen, K. K. W., Steensig, K., Madsen, M., Thim, T., Jensen, L. O., Raungaard, B., Eikelboom, J. W., Kristensen, S. D., Bøtker, H. E., & Mæng, M. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.09.011 · Cited by 11
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial
Sandner, S. E., Schunkert, H., Kastrati, A., Wiedemann, D., Misfeld, M., Böning, A., Tebbe, U., Nowak, B., Stritzke, J., Laufer, G., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz313 · Cited by 11

Authors: Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., Bengtsson, O., Ophuis, T. O., Budaj, A., Theroux, P., Ruda, M., Hamm, C., Goto, S., Spinar, J., Nicolau, J. C., Kiss, R. G., Murphy, S. A., Wiviott, S. D., Held, P., Braunwald, E., & Sabatine, M. S.
Affiliations: Newark Beth Israel Medical Center (US)
Brigham and Women's Hospital (US)
University of Sheffield (GB)
AstraZeneca (Sweden) (SE)
Icahn School of Medicine at Mount Sinai (US)
Canisius-Wilhelmina Ziekenhuis (NL)
Grochowski Hospital (PL)
National Medical Research Center of Cardiology (RU)
Justus-Liebig-Universität Gießen (DE)
Tokai University (JP)
Universidade de São Paulo (BR)
ORCID: Bonaca, Marc P.
Bhatt, Deepak L.
Cohen, Marc
Storey, Robert F.
Magnani, Giulia
Im, Kyungah
Bengtsson, Olof
Budaj, Andrzej
Hamm, Christian
Goto, Shinya
Nicolau, José Carlos
Murphy, Sabina A.
Wiviott, Stephen D.
Sabatine, Marc S.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-05-07
Volume: 372
Issue: 19
Pages: 1791-1800
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1500857
OpenAlex: W2141358924
Cited by: 1,999
References: 32
Citations by year: 2026: 86 · 2025: 99 · 2024: 102 · 2023: 130 · 2022: 163 · 2021: 189 · 2020: 232 · 2019: 205 · 2018: 220 · 2017: 222 · 2016: 236 · 2015: 108
FWCI: 188.81
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
HAL (submittedVersion)
University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
Digital Access to Libraries (submittedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Use Siena air (University of Siena) (submittedVersion)
Funders: Japan Society for the Promotion of Science (24390202)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: ticagrelor, P2Y12 inhibitors, old myocardial infarction, dual antiplatelet therapy, long-term antiplatelet therapy, cardiovascular mortality, myocardial infarction, stroke, intracranial hemorrhage, aspirin, dose comparison, secondary prevention, bleeding risk, cardiovascular risk reduction
MeSH terms: Ticagrelor, Adenosine, Aged, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk, Intracranial Hemorrhages, Kaplan-Meier Estimate, Secondary Prevention, Purinergic P2Y Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks